MX2023002463A - Formulaciones de compuestos antivirales. - Google Patents
Formulaciones de compuestos antivirales.Info
- Publication number
- MX2023002463A MX2023002463A MX2023002463A MX2023002463A MX2023002463A MX 2023002463 A MX2023002463 A MX 2023002463A MX 2023002463 A MX2023002463 A MX 2023002463A MX 2023002463 A MX2023002463 A MX 2023002463A MX 2023002463 A MX2023002463 A MX 2023002463A
- Authority
- MX
- Mexico
- Prior art keywords
- linked
- pharmaceutically acceptable
- pharmaceutical composition
- salt
- amino acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000008300 phosphoramidites Chemical class 0.000 abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- -1 cysteine compound Chemical class 0.000 abstract 1
- 241001493065 dsRNA viruses Species 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000005642 phosphothioate group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica que comprende un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo; en donde X se selecciona de un hidroxilo, un hidroxi1ato de sal metálica, un fosfoéster unido a O, una fosforamidita unida a O, un éster unido a O, un carbamato unido a O, un fosfotioato unido a S o una fosforamidita unida a N, y al menos un excipiente farmacéuticamente aceptable seleccionado de un compuesto de cisteína, un aminoácido, un AFaceti1aminoácido, un ácido o una sal del mismo, o cualquier combinación de los mismos. La composición farmacéutica. se puede usar para el tratamiento eficaz de infecciones víricas en seres humanos y otras especies animales provocadas por virus, en particular, virus de ARN, y se pueden administrar por vía oral o parenteral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071560P | 2020-08-28 | 2020-08-28 | |
| US202163200334P | 2021-03-02 | 2021-03-02 | |
| PCT/US2021/070624 WO2022047441A1 (en) | 2020-08-28 | 2021-05-27 | Formulations of anti-viral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002463A true MX2023002463A (es) | 2023-08-18 |
Family
ID=76502903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002463A MX2023002463A (es) | 2020-08-28 | 2021-05-27 | Formulaciones de compuestos antivirales. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230355649A1 (es) |
| EP (1) | EP4203937A1 (es) |
| JP (1) | JP2023540149A (es) |
| KR (1) | KR20230058107A (es) |
| CN (1) | CN116367837A (es) |
| AU (1) | AU2021334028A1 (es) |
| CA (1) | CA3193447A1 (es) |
| GB (1) | GB2613516A (es) |
| IL (1) | IL301015A (es) |
| MX (1) | MX2023002463A (es) |
| WO (1) | WO2022047441A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202313067A (zh) | 2020-01-27 | 2023-04-01 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
| EP4118085A2 (en) | 2020-03-12 | 2023-01-18 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| AU2021296841A1 (en) | 2020-06-24 | 2023-02-16 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| DK4204421T3 (da) | 2020-08-27 | 2024-05-27 | Gilead Sciences Inc | Forbindelser og fremgangsmåder til behandling af virale infektioner |
| TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR111490A1 (es) * | 2017-05-01 | 2019-07-17 | Gilead Sciences Inc | Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino) |
| EP3651734A1 (en) * | 2017-07-11 | 2020-05-20 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| WO2021168930A1 (zh) * | 2020-02-25 | 2021-09-02 | 顾世海 | 一种瑞德西韦的片剂及其制备方法 |
| CN111135166A (zh) * | 2020-03-05 | 2020-05-12 | 华中农业大学 | 一种由gc376与gs-441524组成的药物组合物及其抑制新冠病毒的用途 |
| CN111494349A (zh) * | 2020-04-30 | 2020-08-07 | 中国人民解放军空军军医大学 | 一种瑞德西韦口腔速溶膜及制备方法 |
| US11020349B1 (en) * | 2020-07-14 | 2021-06-01 | Jubilant Generics Limited | Transmucosal dosage forms of remdesivir |
| CN111603408A (zh) * | 2020-06-23 | 2020-09-01 | 黄铸霖 | 具有抗病毒功效的唇膏 |
| CN112656759B (zh) * | 2021-01-23 | 2022-08-19 | 河南泰丰生物科技有限公司 | 一种瑞德西韦滴眼剂及其制备方法和用途 |
-
2021
- 2021-05-27 MX MX2023002463A patent/MX2023002463A/es unknown
- 2021-05-27 KR KR1020237010127A patent/KR20230058107A/ko active Search and Examination
- 2021-05-27 AU AU2021334028A patent/AU2021334028A1/en active Pending
- 2021-05-27 CA CA3193447A patent/CA3193447A1/en active Pending
- 2021-05-27 EP EP21733356.6A patent/EP4203937A1/en active Pending
- 2021-05-27 JP JP2023537892A patent/JP2023540149A/ja active Pending
- 2021-05-27 US US18/043,518 patent/US20230355649A1/en active Pending
- 2021-05-27 GB GB2303817.7A patent/GB2613516A/en active Pending
- 2021-05-27 CN CN202180070265.7A patent/CN116367837A/zh active Pending
- 2021-05-27 IL IL301015A patent/IL301015A/en unknown
- 2021-05-27 WO PCT/US2021/070624 patent/WO2022047441A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20230355649A1 (en) | 2023-11-09 |
| CA3193447A1 (en) | 2022-03-03 |
| IL301015A (en) | 2023-05-01 |
| AU2021334028A1 (en) | 2023-04-13 |
| JP2023540149A (ja) | 2023-09-21 |
| WO2022047441A1 (en) | 2022-03-03 |
| CN116367837A (zh) | 2023-06-30 |
| EP4203937A1 (en) | 2023-07-05 |
| KR20230058107A (ko) | 2023-05-02 |
| GB2613516A (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002463A (es) | Formulaciones de compuestos antivirales. | |
| TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| WO2006122011A3 (en) | Thiazole compounds and methods of use | |
| JP2017531038A5 (es) | ||
| ES2160046A1 (es) | Derivados pentapeptidicos. | |
| EP2433622B1 (en) | Agent for the prophylaxis and treatment of highly pathogenic infectious diseases | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| MX2010006209A (es) | Derivados de quinoxalinilo. | |
| EA200601281A1 (ru) | Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| CR20220109A (es) | Profármacos antivirales y formulaciones de los mismos | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| WO2006130532A3 (en) | Treatment of liver diseases in which iron plays a role in pathogenesis | |
| NZ600912A (en) | Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection | |
| US20230210848A1 (en) | Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug | |
| KR20220146496A (ko) | 뉴클레오티드계 화합물의 코로나 바이러스 감염증의 치료에의 사용 | |
| EP1201236A4 (en) | MEDICAL COMPOSITIONS FOR PREVENTING THE TREATMENT OF VIRAL MYOCASCHITIS | |
| US20090326037A1 (en) | Medicinal Agent For Treating Viral Infections | |
| DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
| BR112022019198A2 (pt) | Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma | |
| CN114762694B (zh) | 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用 | |
| US20230241037A1 (en) | Cross-linked medication for treatment of coronaviral infection and method of treatment |